Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25
Stocks News & Analysis
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
stocks
Chart of the Week: Why ASX tech is poised for a comeback
The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,381.40 | 9.10 | -0.10% |
| CAC 40 | 8,653.43 | 21.51 | -0.25% |
| DAX 40 | 26,318.77 | 12.30 | -0.05% |
| Dow JONES (US) | 53,730.99 | 39.28 | -0.07% |
| FTSE 100 | 10,759.24 | 73.91 | -0.68% |
| HKSE | 25,396.51 | 43.66 | -0.17% |
| NASDAQ | 26,805.23 | 216.75 | 0.82% |
| Nikkei 225 | 68,308.59 | 784.53 | 1.16% |
| NZX 50 Index | 13,825.30 | 87.64 | 0.64% |
| S&P 500 | 7,794.66 | 46.16 | 0.60% |
| S&P/ASX 200 | 9,188.50 | 4.40 | -0.05% |
| SSE Composite Index | 3,926.96 | 19.71 | -0.50% |